🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04843215
Recruiting Not applicable

A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer

NCT04843215 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Started
2021-01-01
Last updated
2021-05-10

Condition(s) studied

Gastric Cancer

Investigational drug(s) / intervention(s)

Type of omentectomy

Type of omentectomy: Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.

Study summary

This is a phase III, multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of omentectomy for advanced gastric cancer on patient survival.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16); 2. Physical condition and organ function allows to tolerable abdominal surgery; 3. Willing and able to comply with the program during the study period; 4. Written informed consent provided; 5. ≥ 18 and ≤ 70 years of age; preoperative gastric cancer patients with pathologically confirmed; 6. With more than a 6-month life expectancy; 7. No other serious concomitant diseases; Sufficient organ functions; 8. No previous history of chemotherapy or radiotherapy; 9. All patients accept 8 cycles XELOX chemotherapy regimen; 10. Clinical stage: T3-4aN0-+M0; 11 . Macroscopic types :Borrmann I-III; 12\. Not greater curvature tumor; with distal or total gastrectomy; 13. No previous surgery for any abdominal disease, except an appendectomy for appendicitis, a laparoscopic cholecystectomy for gallbladder stones; No previous history of peritonitis, pancreatitis; 14. Karnofsky performance status (KPS)\>60; Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1. Exclusion Criteria: Pregnancy or breast feeding; 2. Patients with Serious liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease or uncontrolled diabetes, hypertension and other chronic systemic diseases, heart disease with Clinical symptoms, such as congestive heart failure, coronary heart disease symptoms, drug is difficult to control arrhythmia, hypertension, or six months had a myocardial infarction attack, or cardiac insufficiency; 3. Organ transplantation patients need immunosuppressive therapy; 4. Severe recurrent infections were not controlled or with other serious concomitant diseases; 5. Patients got other primary malignant tumors (except curable skin basal cell carcinoma and cervical cancer in situ) except gastric cancer within 5 years; 6. Psychiatric disease which require treatment; 7. Have the history of organ transplantation; 8. Within 6 months before study starts and in the process of this study, patients participate in other clinical researches. 9. Advanced gastric cancer with omentum invasion 10. Patients can't treated with XELOX after surgery; 11 . Macroscopic types : Borrmann IV; 12. Tumor invasion of adjacent organ (T4b) or with distant metastasis#M1 #; 13. Tumor invasion the greater curvature invasion.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital Tianjin Tianjin Municipality Recruiting

More Tianjin Medical University Cancer Institute and Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04843215 on ClinicalTrials.gov ↗ ← All trials in China